Compare KRNY & MRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KRNY | MRVI |
|---|---|---|
| Founded | 1884 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 504.9M | 472.8M |
| IPO Year | 2014 | 2020 |
| Metric | KRNY | MRVI |
|---|---|---|
| Price | $7.98 | $3.28 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $8.00 | $4.13 |
| AVG Volume (30 Days) | 286.4K | ★ 1.9M |
| Earning Date | 04-23-2026 | 05-11-2026 |
| Dividend Yield | ★ 5.47% | N/A |
| EPS Growth | ★ 130.22 | 14.29 |
| EPS | ★ 0.30 | N/A |
| Revenue | $2,580,000.00 | ★ $185,743,000.00 |
| Revenue This Year | $3.89 | $12.44 |
| Revenue Next Year | $17.52 | $7.90 |
| P/E Ratio | $26.80 | ★ N/A |
| Revenue Growth | ★ 36.00 | N/A |
| 52 Week Low | $5.76 | $1.67 |
| 52 Week High | $8.50 | $4.11 |
| Indicator | KRNY | MRVI |
|---|---|---|
| Relative Strength Index (RSI) | 61.88 | 57.59 |
| Support Level | $7.77 | $3.25 |
| Resistance Level | $8.42 | $3.93 |
| Average True Range (ATR) | 0.16 | 0.16 |
| MACD | 0.08 | 0.04 |
| Stochastic Oscillator | 76.47 | 86.11 |
Kearny Financial Corp is a federally-chartered stock savings bank. The bank is engaged in the business of attracting deposits from the general public in New Jersey and New York, and using these deposits, together with other funds, to originate or purchase loans for its portfolios and invest in securities. The bank's loan portfolio is chiefly comprised of loans collateralized by commercial and residential real estate. The bank's primary source of income is net interest income.
Maravai LifeSciences Holdings Inc is a life sciences company that provides critical products that drive the development of groundbreaking vaccines, drug therapies, cell and gene therapies, and diagnostics. The group's solutions empower research into human diseases and support the entire biopharmaceutical development process from early discovery to commercialization. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.